
Cipla Limited has informed the Exchange regarding a press release dated October 04, 2021, titled "Eli Lilly and Cipla enter into a strategic partnership in India to enhance access to Lilly s key diabetes products".
Filed with NSE · · 3 pages · English
Cipla Ltd announced a strategic partnership with Eli Lilly to enhance access to diabetes products in India, specifically Humalog and Trulicity. Under this agreement, Lilly will transfer its rights to sell and distribute these products to Cipla, pending regulatory approvals. Cipla aims to leverage its distribution strengths to improve patient access to these diabetes treatments. The partnership aligns with both companies' goals of providing innovative healthcare solutions to patients in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Limited has informed the Exchange regarding a press release dated October 04, 2021, titled "Eli Lilly and Cipla enter into a strategic partnership in India to enhance access to Lilly s key diabetes products".
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla